Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
danlou tablet + salvia miltiorrhiza + ligustrazine
- Development stage
- Phase 4
- Lead developer
- Traditional Chinese Medicine Hospital of Tailai County
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of **Danlou tablet**, **Salvia miltiorrhiza** (Danshen), and **ligustrazine** (tetramethylpyrazine) is a therapeutic regimen used in Traditional Chinese Medicine (TCM) for the treatment of cardiovascular conditions, specifically **chronic stable angina**. Danlou tablet is a standardized Chinese patent medicine composed of ten herbs (including *Trichosanthes kirilowii*, *Allium macrostemon*, and *Pueraria lobata*) designed to resolve phlegm, remove blood stasis, and unblock the collaterals. Salvia miltiorrhiza and ligustrazine (often administered together as a fixed-dose injection) provide potent synergistic effects by promoting blood circulation, inhibiting platelet aggregation, and inducing vasodilation. This combination therapy targets the 'phlegm-stasis' pathogenesis common in coronary heart disease, aiming to improve myocardial blood supply, reduce inflammatory markers like C-reactive protein and NF-kappa B, and alleviate anginal symptoms. The regimen has been studied and utilized by institutions such as the **Traditional Chinese Medicine Hospital of Tailai County** to enhance clinical outcomes in patients with stable coronary artery disease.
- Brand names
- Danshen Chuanxiongzine Injection
- Other names
- Danlou PianDanlou Tablet + Danshen + ChuanxiongzineDanlou Tablet + Salvia miltiorrhiza + Tetramethylpyrazine
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)NF-κBNLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TNFA (Tumor necrosis factor alpha (soluble))CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on danlou tablet + salvia miltiorrhiza + ligustrazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on danlou tablet + salvia miltiorrhiza + ligustrazine.